Developing antibodies to inhibit important enzymes in the body
Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical Importance
This study is working on new treatments using special antibodies that can block certain enzymes linked to diseases like cancer and viral infections, aiming to create safer and more effective options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11079456 on NIH RePORTER |
What this research studies
This research focuses on creating therapeutic monoclonal antibodies that can effectively inhibit proteases, which are enzymes that play crucial roles in various physiological processes and diseases. The approach involves developing high-selectivity antibodies that can cross the blood-brain barrier and provide safer and more effective treatment options compared to traditional small-molecule inhibitors. The research aims to streamline the discovery and engineering of these antibodies, addressing challenges in their routine development. Patients may benefit from new therapies targeting conditions influenced by proteases, including cancer and viral infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from diseases where proteases play a significant role, such as certain cancers or viral infections.
Not a fit: Patients with conditions unrelated to protease activity may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for diseases by providing highly specific and effective protease inhibitors.
How similar studies have performed: Other research has shown promise in using monoclonal antibodies for therapeutic purposes, indicating potential success for this novel approach.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Ge, Xin — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Ge, Xin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.